Journal
PHARMACOGENOMICS JOURNAL
Volume 8, Issue 2, Pages 147-151Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.tpj.6500449
Keywords
prostate cancer; UGT2B17; deletion; androgen metabolism; testosterone; dihydrotestosterone
Categories
Ask authors/readers for more resources
Metabolism of androgens includes glucuronidation, the major pathway of steroid elimination in several steroid target tissues. Glucuronidation is catalysed by UDP-glucuronosyltransferases (UGTs). UGT2B17 has been shown to be particularly active against androgens and is highly abundant in the prostate. Recently, we discovered that deletion of the UGT2B17 gene is associated with low or undetectable urinary testosterone levels. Here, we determined the phenotypic outcome of the deletion by quantifying the UGT2B17 mRNA expression in normal prostate tissues in individuals with different genotypes. Additionally, the frequency of UGT2B17 deletion polymorphism was studied in a Swedish population-based case-control study including 176 patients diagnosed with prostate cancer and 161 controls. We found that the individuals homozygous for the insertion allele expressed 30 times more UGT2B17 mRNA in prostate tissue than the heterozygotes. Carriers of the deletion allele had a significantly increased risk of prostate cancer (OR = 2.07; 95% CI = 1.32-3.25). In conclusion, these results showthe UGT2B17 deletion polymorphism is associated with prostate cancer risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available